Two combination chemotherapy protocols, CMF (cyclophosphamide, methotrexate, fluorouracil) and CMFH (CMF plus homoharringtonine), were tested in advanced breast cancer patients. The response rate of CMF was 50% in 44 cases, and that of CMFH was 54.16% in 48 cases; the difference was not significant. There was also no difference between the median duration of response and the median survival of the two protocols. It was concluded that the addition of homoharringtonine to the CMF protocol gave no additional benefit.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG., ValagussaP.: Dose-response effect of adjuvant chemotherapy in breast cancer.New Engl. J. Med., 304: 10–15, 1981.
2.
CoonleyC.J., WarrellR.P.Jr., YoungC.W.: Phase I trial of homoharringtonine administered as a 5-day continuous infusion.Cancer Treat. Rep., 67: 693–696, 1983.
3.
Leukemia Coordination Group Fukien Province:Homoharringtonine and harringtonine in acute nonlymphocytic leukemia, clinical observation of 40 cases.Chinese J. Int. Med., 17: 162–164, 1978.
4.
ZhenkunPan, ZhongyiChang, YongchaoWang, KunLee, ChiangyiSze, XiujuanJi, YutingXu, ZhanrongLi, JuiHan: Studies on harringtonine as a new antitumor drug. In: Cancer Research in the People's Republic of China and the United States of America Epidemiology Causation and Approaches to Therapy.MarksP.A. (ed.), pp. 261–267, Grune & Stratton, New York, 1981.
5.
SteelR.G.D., TorrieJ.H.: Principals and Procedures of Statistics. p. 405. McGraw-Hill, New York, 1960.
6.
TipingZhao, GenxiongDing, HaoyongGao, ZhenzhouShen, YueyunKatherine Li: Homoharringtonine in the treatment of advanced breast cancer.Tumor, 4: 117–119, 1984.
